Literature DB >> 22972817

Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia.

Rodrigo E Mendes1, Lalitagauri M Deshpande, Davida S Smyth, Bo Shopsin, David J Farrell, Ronald N Jones.   

Abstract

A total of 434 methicillin-resistant Staphylococcus aureus (MRSA) baseline isolates were collected from subjects enrolled in a prospective, double-blind randomized trial comparing linezolid versus vancomycin for the treatment of nosocomial pneumonia. Isolates were susceptibility tested by broth microdilution, examined for inducible clindamycin resistance by D-test, and screened for heterogeneous resistance to vancomycin (hVISA) by the Etest macromethod. All strains were subjected to Panton-Valentine leukocidin (PVL) screening, and SCCmec, pulsed-field gel electrophoresis (PFGE), and spa typing. Selected strains were evaluated by multilocus sequence typing (MLST). Clonal complexes (CCs) were assigned based on the spa and/or MLST results. Most strains were CC5 (56.0%), which originated from North America (United States) (CC5-MRSA-SCCmec II/IV; 70.0%), Asia (CC5-MRSA-II; 14.0%) and Latin America (CC5-MRSA-I/II; 12.3%). The second- and third-most-prevalent clones were CC8-MRSA-IV (23.3%) and CC239-MRSA-III (11.3%), respectively. Furthermore, the CC5-MRSA-I/II clone predominated in Asia (50.7% within this region) and Latin America (66.7%), followed by CC239-MRSA-III (32.8% and 28.9%, respectively). The European strains were CC8-MRSA-IV (34.5%), CC22-MRSA-IV (18.2%), or CC5-MRSA-I/II/IV (16.4%), while the U.S. MRSA isolates were CC5-MRSA-II/IV (64.4%) or CC8-MRSA-IV (28.8%). Among the U.S. CC8-MRSA-II/IV strains, 73.7% (56/76 [21.2% of all U.S. MRSA strains]) clustered within USA300. One strain from the United States (USA800) was intermediate to vancomycin (MIC, 4 μg/ml). All remaining strains were susceptible to linezolid, daptomycin, vancomycin, and teicoplanin. hVISA strains (14.5%) were predominantly CC5-MRSA-II, from South Korea, and belonged to a single PFGE type. Overall, each region had two predominant clones. The USA300 rate corroborates previous reports describing increased prevalence of USA300 strains causing invasive infections. The prevalence of hVISA was elevated in Asia, and these strains were associated with CC5.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22972817      PMCID: PMC3486224          DOI: 10.1128/JCM.02024-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  52 in total

1.  Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006.

Authors:  Gyungtae Chung; Jeongok Cha; Sunyoung Han; Heesun Jang; Kyeongmin Lee; Jaeil Yoo; Jeongsik Yoo; Hongbin Kim; Soohoon Eun; Bongsu Kim; Ok Park; Yeong seon Lee
Journal:  J Microbiol Biotechnol       Date:  2010-03       Impact factor: 2.351

2.  Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus.

Authors:  Ki-Ho Park; Eun Sil Kim; Hee Seung Kim; Su-Jin Park; Kyung Mi Bang; Hyun Jung Park; So-Youn Park; Song Mi Moon; Yong Pil Chong; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jin-Yong Jeong; Mi-Na Kim; Jun Hee Woo; Yang Soo Kim
Journal:  J Antimicrob Chemother       Date:  2012-04-25       Impact factor: 5.790

3.  Predominance and emergence of clones of hospital-acquired methicillin-resistant Staphylococcus aureus in Malaysia.

Authors:  Ehsanollah Ghaznavi-Rad; Mariana Nor Shamsudin; Zamberi Sekawi; Liew Yun Khoon; Mohammad Nazri Aziz; Rukman Awang Hamat; Norlijah Othman; Pei Pei Chong; Alex van Belkum; Hamed Ghasemzadeh-Moghaddam; Vasanthakumari Neela
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

4.  MRSA genotypes in Turkey: persistence over 10 years of a single clone of ST239.

Authors:  Emine Alp; Corné H W Klaassen; Mehmet Doganay; Ulku Altoparlak; Kemalettin Aydin; Aynur Engin; Cigdem Kuzucu; Cuneyt Ozakin; Mehmet Ali Ozinel; Ozge Turhan; Andreas Voss
Journal:  J Infect       Date:  2009-04-22       Impact factor: 6.072

5.  Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid.

Authors:  Rodrigo E Mendes; Helio S Sader; Lalitagauri M Deshpande; Binh An Diep; Henry F Chambers; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2009-11-25       Impact factor: 5.948

6.  Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007.

Authors:  Deron C Burton; Jonathan R Edwards; Teresa C Horan; John A Jernigan; Scott K Fridkin
Journal:  JAMA       Date:  2009-02-18       Impact factor: 56.272

7.  Dissemination of methicillin-resistant Staphylococcus aureus USA300 sequence type 8 lineage in Latin America.

Authors:  Jinnethe Reyes; Sandra Rincón; Lorena Díaz; Diana Panesso; Germán A Contreras; Jeannete Zurita; Carlos Carrillo; Adele Rizzi; Manuel Guzmán; Javier Adachi; Shahreen Chowdhury; Barbara E Murray; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2009-12-15       Impact factor: 9.079

8.  Decline of EMRSA-16 amongst methicillin-resistant Staphylococcus aureus causing bacteraemias in the UK between 2001 and 2007.

Authors:  Matthew J Ellington; Russell Hope; David M Livermore; Angela M Kearns; Katherine Henderson; Barry D Cookson; Andrew Pearson; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2009-12-24       Impact factor: 5.790

9.  Hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) in Italy.

Authors:  Floriana Campanile; Dafne Bongiorno; Sonia Borbone; Stefania Stefani
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-06-24       Impact factor: 3.944

10.  Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis.

Authors:  Hajo Grundmann; David M Aanensen; Cees C van den Wijngaard; Brian G Spratt; Dag Harmsen; Alexander W Friedrich
Journal:  PLoS Med       Date:  2010-01-12       Impact factor: 11.069

View more
  25 in total

1.  In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis.

Authors:  Edgar H Sanchez; Rodrigo E Mendes; Helio S Sader; Genève M Allison
Journal:  J Antimicrob Chemother       Date:  2016-02-09       Impact factor: 5.790

2.  Update on linezolid in vitro activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013.

Authors:  Rodrigo E Mendes; Patricia A Hogan; Jennifer M Streit; Ronald N Jones; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.

Authors:  Rodrigo E Mendes; Helio S Sader; Robert K Flamm; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

4.  Prevalence and molecular epidemiology of methicillin-resistant Staphylococcus aureus in a tertiary Greek hospital.

Authors:  M Kachrimanidou; E Tsorlini; E Katsifa; S Vlachou; S Kyriakidou; K Xanthopoulou; K Tsergouli; T Samourli; A Papa
Journal:  Hippokratia       Date:  2014-01       Impact factor: 0.471

5.  Disruption of staphylococcal aggregation protects against lethal lung injury.

Authors:  Jaime L Hook; Mohammad N Islam; Dane Parker; Alice S Prince; Sunita Bhattacharya; Jahar Bhattacharya
Journal:  J Clin Invest       Date:  2018-02-12       Impact factor: 14.808

6.  Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?

Authors:  Kimberly C Claeys; Abdalhamid M Lagnf; Jessica A Hallesy; Matthew T Compton; Alison L Gravelin; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

7.  Cytotoxic Virulence Predicts Mortality in Nosocomial Pneumonia Due to Methicillin-Resistant Staphylococcus aureus.

Authors:  Hannah R Rose; Robert S Holzman; Deena R Altman; Davida S Smyth; Gregory A Wasserman; Jared M Kafer; Michelle Wible; Rodrigo E Mendes; Victor J Torres; Bo Shopsin
Journal:  J Infect Dis       Date:  2014-10-07       Impact factor: 5.226

8.  Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.

Authors:  Robert K Flamm; Paul R Rhomberg; Nachum Kaplan; Ronald N Jones; David J Farrell
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

9.  Endovascular infections caused by methicillin-resistant Staphylococcus aureus are linked to clonal complex-specific alterations in binding and invasion domains of fibronectin-binding protein A as well as the occurrence of fnbB.

Authors:  Yan Q Xiong; Batu K Sharma-Kuinkel; Nadia N Casillas-Ituarte; Vance G Fowler; Thomas Rude; Alex C DiBartola; Roberto D Lins; Wessam Abdel-Hady; Steven K Lower; Arnold S Bayer
Journal:  Infect Immun       Date:  2015-09-28       Impact factor: 3.441

10.  Performance of BD Max StaphSR for Screening of Methicillin-Resistant Staphylococcus aureus Isolates among a Contemporary and Diverse Collection from 146 Institutions Located in Nine U.S. Census Regions: Prevalence of mecA Dropout Mutants.

Authors:  Rodrigo E Mendes; Amy A Watters; Paul R Rhomberg; David J Farrell; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2015-11-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.